MEDAREX, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 4132
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 3164
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 198

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9217033 Monoclonal antibodies against Glypican-3Feb 10, 14Dec 22, 15[A61K, C07K]
8158419 Transgenic non-human animals for producing chimeric antibodiesSep 26, 08Apr 17, 12[C12N]
7851181 Neutralizing human anti-IGFR antibodyAug 08, 07Dec 14, 10[C12P]
5877281 Developmentally-regulated endothelial cell locus-1Jun 05, 96Mar 02, 99[C12N, C07K]
5874562 Nucleic acid encoding developmentally-regulated endothelial cell locus-1Jun 07, 95Feb 23, 99[C12N]
5635600 Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytesDec 27, 94Jun 03, 97[C07K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2015/0307,609 OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOFAbandonedJul 09, 15Oct 29, 15[A61K, C07K]
2012/0276,086 MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUESAbandonedApr 18, 12Nov 01, 12[A61K, C12N, A61P, C07K]
2011/0182,904 ANTIBODIES TO BONE MORPHOGENIC PROTEINS AND RECEPTORS THEREFOR AND METHODS FOR THEIR USEAbandonedSep 05, 07Jul 28, 11[A61K, C12P, C12N, A61P, C07K]
2011/0123,440 Altered Antibody FC Regions and Uses ThereofAbandonedMar 28, 06May 26, 11[A61K, C12P, A61P, C07K]
2010/0209,435 Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway InhibitorsAbandonedFeb 15, 10Aug 19, 10[A61K, C07H, C12P, C12N, A61P, C07K]
2010/0104,509 HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOFAbandonedDec 13, 07Apr 29, 10[A61K, C07K]
2010/0104,564 Altered Antibody Fc Regions and Uses ThereofAbandonedMar 28, 06Apr 29, 10[A61K, C12P, G01N, A61P, C07K]
2009/0297,438 Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)AbandonedFeb 17, 06Dec 03, 09[A61K, C07H, C12Q, C12N, A01K, A61P, C07K]
2009/0214,544 Method of treating cd30 positive lymphomasAbandonedApr 25, 06Aug 27, 09[A61K]
2009/0214,547 BINDING MEMBER TOWARDS PNEUMOLYSINAbandonedAug 22, 05Aug 27, 09[A61K, C07H, C12N, G01N, A61P, C07K]
2009/0175,886 MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUESAbandonedJan 17, 07Jul 09, 09[A61K, C12N, A61P, C07K]
2009/0162,372 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USEAbandonedNov 14, 08Jun 25, 09[A61K, A61P, C07K]
7521053 Angiopoietin-2 specific binding agentsExpiredOct 10, 02Apr 21, 09[A61K, C07K]
7501552 Transgenic non-human animals for producing chimeric antibodiesExpiredDec 10, 04Mar 10, 09[C12P, A01K]
2009/0028,857 PD-1 ANTIBODIES IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOFAbandonedJul 23, 08Jan 29, 09[A61K, A61P]
2008/0279,868 Antibody-Drug Conjugates and Methods of UseAbandonedSep 26, 06Nov 13, 08[A61K, A61P]
2008/0253,962 Irta-4 Antibodies and Their UsesAbandonedSep 19, 05Oct 16, 08[A61K, C12P, C12N, A61P, C07K]
2008/0247,944 Irta-2 Antibodies and Their UsesAbandonedJan 12, 06Oct 09, 08[A61K, C12P, C12N, A61P, C07K]
2008/0226,646 USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF TUMORSAbandonedMar 10, 08Sep 18, 08[A61K, C12N, A61P, C07K]
2008/0226,647 Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I InterferonAbandonedMay 09, 08Sep 18, 08[A61K, C12N, A61P]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.